ADC Therapeutics SA
NYSE:ADCT

Watchlist Manager
ADC Therapeutics SA Logo
ADC Therapeutics SA
NYSE:ADCT
Watchlist
Price: 1.83 USD 4.57%
Market Cap: 176.9m USD

Operating Margin
ADC Therapeutics SA

-214%
Current
-333%
Average
-7.6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-214%
=
Operating Profit
-264.2m
/
Revenue
123.5m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
CH
ADC Therapeutics SA
NYSE:ADCT
176.9m USD
-214%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
303.2B USD
28%
US
Amgen Inc
NASDAQ:AMGN
146.3B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
114.4B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
108.8B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
132.7B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
75B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
38.1B EUR
-15%

ADC Therapeutics SA
Glance View

Market Cap
176.9m USD
Industry
Biotechnology

ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.

ADCT Intrinsic Value
4.91 USD
Undervaluation 63%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-214%
=
Operating Profit
-264.2m
/
Revenue
123.5m
What is the Operating Margin of ADC Therapeutics SA?

Based on ADC Therapeutics SA's most recent financial statements, the company has Operating Margin of -214%.

Back to Top